Fed’s Powell opens door to potential rate cuts at Jackson Hole
SAN FRANCISCO—Carroll Patrick Harrison, the Chief Medical (TASE:BLWV) Officer of Hims & Hers Health, Inc. (NYSE:HIMS), has recently sold a significant portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Harrison sold 23,287 shares of Class A Common Stock on March 18, 2025, at a price of $34.31 per share, amounting to a total transaction value of $798,976.
In addition to this sale, Harrison also performed other transactions involving Hims & Hers stock. On March 14, 2025, he disposed of 3,162 shares at $33.14 per share to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs), totaling $104,788.
These transactions were part of a pre-arranged trading plan adopted on November 8, 2024, under Rule 10b5-1, which allows company insiders to sell a predetermined number of shares at a predetermined time.
Following these transactions, Harrison holds 209,661 shares of Hims & Hers Class A Common Stock directly.
In other recent news, Hims & Hers Health, Inc. reported significant developments impacting its business and investor perspectives. BofA Securities has raised its price target for the company to $22, up from $21, although it maintained an Underperform rating. This adjustment follows an analysis of sales data indicating accelerated growth in the GLP-1 product segment, with year-over-year sales increasing by 124% in February. The projected online revenue for the first quarter of 2025 is estimated to be between $594 million and $622 million, surpassing the consensus estimate of $523.9 million. However, concerns were raised about a potential slowdown in core growth and the execution risks associated with semaglutide, which comprises nearly half of the company’s sales.
Additionally, the FDA extended enforcement timelines for compounding semaglutide, a key product for Hims & Hers, until April 2025, providing some regulatory clarity. Meanwhile, Citi maintained a Sell rating with a $27 price target, citing ongoing legal challenges related to the FDA’s removal of tirzepatide from the drug shortage list. The legal proceedings could impact Hims & Hers’ operations, as the availability of tirzepatide and semaglutide are crucial to its business model. Investors are closely monitoring these developments, as they may influence the company’s future performance and regulatory compliance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.